We forecast one to two GLP-1 launches annually starting in 2026, with the first oral entrant expected by 2027
If finalized, the move could impact telehealth firms that rely on outsourcing facilities to produce these drugs in bulk, while bolstering Novo and Lilly's efforts against unauthorized versions that are eating into sales of their blockbuster treatments
To view or add a comment, sign in STOX the Money Cutting Through the Noise
Beyond simple efficacy, however, their popularity has also been buoyed by Hollywood buzz, with high-profile celebs singing their praises
Although it remains unknown why NAC failed to improve clinical outcomes in this trial, a leading candidate explanation is that NAC failed to significantly affect the hypothesized mechanism of interest, brain glutamate concentrations
10.1016/j.fsi.2020.03.041 33 JoblingM